PART 1: The Big Pharma Perspective

Welcome to a 2-part series in which we identify and distill some key learnings for partnering success in today's life sciences sector.

Perhaps one of the most valuable take-aways from the COVID-19 pandemic response is the sheer scale of what may be achieved through effective collaboration. Over the next three episodes, we'll talk to a range of different stakeholders, asking them to pass on their tips for what works and what doesn't in this crucial aspect.

In this first episode, Dr Marianne De Backer, a Member of the Executive Committee and Executive Vice President of Strategy, Business Development & Licensing, and Open Innovation at Bayer Pharmaceuticals, shares her experience as a driving force behind Bayer’s significant recent moves in the cell and gene therapy area.